Hikma Pharmaceuticals 

GBX1,956
215
-GBX36-1.81% Friday 15:36

統計

當日最高
2,004
當日最低
1,955
52週最高
2,165
52週最低
1,711
成交量
248,518
平均成交量
343,705
市值
4.4B
市盈率
30.51
股息收益率
3.16%
股息
61.89

即將到來

股息

3.16%股息收益率
10年增長
16.57%
5年增長率
14.5%
3年增長率
17.92%
1年增長率
25.26%

收益

8Aug預期
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Q2 2024
0
33.21
66.42
99.63
預期每股收益
N/A
實際每股收益
99.63404

人們還關注

此列表基於在 Stock Events 上關注 HIK.LSE 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Show more...
首席執行官
Engineer Said Samih Taleb Darwazah
員工
9100
國家
GB
ISIN
GB00B0LCW083

上市公司